Pharma BD Deal Intelligence

Servier / Shire plc (Oncology Business)

2018 · Asset Purchase · $2.4B · Complete

Announcement Sentiment

Positive

Servier acquired Shire's global oncology business for $2.4B cash, announced April 16, 2018 and completed August 31, 2018. Includes Oncaspar (pegaspargase, ALL), Onivyde ex-US (liposomal irinotecan, metastatic pancreatic cancer), calaspargase pegol (NDA pending at deal time; subsequently FDA-approved as Asparlas on December 20, 2018 under Servier Pharmaceuticals LLC), and two early-stage immuno-oncology collaborations. Establishes Servier's first direct US commercial presence via newly formed Servier Pharmaceuticals LLC in Boston. Revenue multiple of 9.2x 2017 sales of $262M.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Apr 16, 2018
Closed Aug 31, 2018
Deal value $2.4B
Deal type Asset Purchase
Therapeutic area Acute lymphoblastic leukemia, metastatic pancreatic cancer
Indications Acute lymphoblastic leukemia, metastatic pancreatic cancer
Key assets Oncaspar (pegaspargase), Onivyde (irinotecan liposomal), Calaspargase pegol
Mechanism PEGylated L-asparaginase (Oncaspar/Calaspargase); liposomal irinotecan topoisomerase I inhibitor (Onivyde)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals